Compare · Head-to-head
Hexarelin vs MGF E-domain.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with Hexarelin, then use the table to confirm fit.
MGF is the cleaner first research read for localized training or tissue-repair questions; hexarelin belongs in a higher-risk GH-secretagogue discussion because it is more systemic and has endocrine overlap.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
Search intent
Why this comparison deserves its own page
This is a performance and recovery comparison between a GH secretagogue and a localized repair/growth-factor style peptide.
Use this pair for muscle and recovery intent. MGF is easier to frame around localized recovery questions, while hexarelin needs stronger caution around endocrine effects, appetite, prolactin/cortisol concerns, and stack overlap.
01 · At a glance
| Decision factor | Hexarelin | MGF E-domain |
|---|---|---|
| Primary fit | muscle growth & strength and sleep & relaxation comparisons | muscle growth & strength and tissue repair & recovery comparisons |
| Evidence | Tier B-C | Tier C |
| Risk | high | extreme |
| Experience level | advanced | advanced |
| Budget tier | mid | mid |
| Administration route | subcutaneous, intravenous | subcutaneous |
02 · Use case & timing
| Decision factor | Hexarelin | MGF E-domain |
|---|---|---|
| Goal fit | Muscle Growth & Strength, Sleep & Relaxation, GH Axis Optimization | Muscle Growth & Strength, Tissue Repair & Recovery |
| What users compare it for | GH-axis modulation; sleep architecture research interest. | Muscle repair signaling in preclinical models. |
| Onset timeline | Acute endocrine effects; sleep effects studied overnight. | Preclinical outcomes vary by model. |
| Main tradeoff | Potential upside comes with much more safety and screening caution than lower-risk alternatives. | Potential upside comes with much more safety and screening caution than lower-risk alternatives. |
03 · Safety & restrictions
| Decision factor | Hexarelin | MGF E-domain |
|---|---|---|
| Adverse effects | Endocrine spillover (ACTH, cortisol, prolactin). | Limited data; growth-factor class concerns apply. |
| Contraindications | No formal label. | No human data. |
| Interaction notes | Unknown; caution with other GH-axis compounds. | Unknown. |
| Regulatory status | Not approved | Not approved |
| FDA flag | FDA status unclear | FDA status unclear |
| WADA status | WADA S2 | WADA S2 |
04 · Age & monitoring
| Decision factor | Hexarelin | MGF E-domain |
|---|---|---|
| Supported age ranges | No age guidance yet | No age guidance yet |
| Life-stage note | Not yet documented | Not yet documented |
| Monitoring burden | Not specified | Not specified |
| Follow-up cadence | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | Hexarelin | MGF E-domain |
|---|---|---|
| Typical cycle cost | No reliable estimate yet | No reliable estimate yet |
| Estimated monthly cost | No reliable estimate yet | No reliable estimate yet |
| Cost confidence | No estimate | No estimate |
06 · Before you buy
| Decision factor | Hexarelin | MGF E-domain |
|---|---|---|
| Tracked vendor listings | 0 listings | 0 listings |
| Sourcing note | No tracked product page yet, so sourcing takes more manual review. | No tracked product page yet, so sourcing takes more manual review. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly |
FAQ · Pair-specific
Is hexarelin stronger than MGF?
They are not interchangeable. Hexarelin is a GH secretagogue with systemic endocrine effects; MGF is usually discussed around localized repair and training adaptation.
Which is better for recovery?
For a narrow tissue-repair question, MGF is usually the more specific comparison. For systemic GH-axis effects, hexarelin is more relevant but carries more monitoring burden.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.